• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Evolus Inc (NQ: EOLS )

    17.02 +0.82 (+5.06%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 901,431
    Open 16.24
    Bid (Size) 16.78 (1)
    Ask (Size) 17.10 (5)
    Prev. Close 16.20
    Today's Range 16.01 - 17.10
    52wk Range 7.440 - 17.70
    Shares Outstanding 54,576,156
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Analyst Scoreboard: 4 Ratings For Evolus
    Via Benzinga

    Performance

    YTD
    +70.37%
    +70.37%
    1 Month
    +9.24%
    +9.24%
    3 Month
    +53.61%
    +53.61%
    6 Month
    +23.74%
    +23.74%
    1 Year
    +96.31%
    +96.31%

    More News

    Read More
    Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
    From Evolus
    Via Business Wire
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Evolus: Chiseling Away At The Aesthetic Market
    Via Talk Markets
    EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
    Via Investor's Business Daily
    Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
    From Evolus
    Via Business Wire
    Evolus to Hold Investor Day on September 12, 2024
    From Evolus
    Via Business Wire
    Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
    From Evolus, Inc.
    Via Business Wire
    Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From Evolus
    Via Business Wire
    Evolus to Report Second Quarter Financial Results on July 31, 2024
    From Evolus
    Via Business Wire
    Evolus Announces Appointment of Albert G. White III to Board of Directors
    From Evolus
    Via Business Wire
    Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
    From Evolus
    Via Business Wire
    Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
    From Evolus
    Via Business Wire
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
    From Evolus
    Via Business Wire
    Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
    From Evolus
    Via Business Wire
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
    From Evolus, Inc.
    Via Business Wire
    EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Evolus Reports First Quarter 2024 Results and Provides Business Update
    From Evolus
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Evolus to Report First Quarter Financial Results on May 7, 2024
    From Evolus
    Via Business Wire
    Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
    From Evolus
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.